Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The poor prognosis of patients with drug resistant ovarian cancer and the lack of targeted therapy have raised the need for alternative treatments. Albendazole (ABZ) is an anti-parasite compound capable of impairing microtubule formation. We hypothesized that ABZ could be repurposed as a potential anti-angiogenic drug due to its potent inhibition of vascular endothelial growth factor (VEGF) in ovarian cancer with ascites. However, the poor aqueous solubility of ABZ limits its potential for cancer therapy. In this study, we have assembled ABZ with bovine serum albumin into nanoparticles with a size range of 7-10 nm (BSA-ABZ) and 200-250 nm (Nab-ABZ). We further examined the anticancer effects of ABZ carrying nanoparticles in ovarian cancer cells, in both in vitro and in vivo models. RESULTS: Drug release studies demonstrated that about 93% of ABZ was released from BSA-ABZ 10 nm in comparison to 83% from Nab-ABZ 200 nm at pH 7.4 in 8 days. In vitro cell proliferation studies showed that the BSA-ABZ 10 nm exhibited the highest killing efficacy of ovarian cancer cells with surprisingly least toxicity to healthy ovarian epithelial cells. Confocal microscopy and fluorescence activated cell sorting analysis (FACS) revealed more efficient internalization of the BSA-ABZ 10 nm by cancer cells. For in vivo studies, we examined the tumor growth, ascites formation and the expression of VEGF and secreted protein acidic and rich in cysteine (SPARC) in tumor samples and only VEGF in plasma samples. The BSA-ABZ 10 nm reduced the tumor burden significantly (p < 0.02) at a much lower drug dose (10 μg/ml) compare to free drug. Both formulations were capable of suppressing the ascites volume significantly (p < 0.05) and reducing the number of ascites cells. The expression of VEGF and SPARC was also reduced, which indicates the underlying therapeutic mechanism of the ABZ. CONCLUSION: Our data suggest that the BSA-ABZ may hold promise for the treatment and control of progression of ovarian cancer with ascites. However further studies are required to examine the efficacy of both the formulations in aggressive models of recurrent ovarian cancer with respect to particle size and dosing parameters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“In addition, nanoparticles of small particle diameter (<100 nm) and hydrophilic properties are capable of avoiding opsonisation and mononuclear phagocytic system (MPS) degradation resulting in enhanced blood circulation time [30,31].”
BackgroundStrategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Yin Win, K., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.07.050 · Cited by 1,452 · cited 1×
“A literature search revealed that the in-vivo efficacy of nanoparticles depends on the uptake of nanoparticles by the tumor with the uptake being increased as particle size decreased [26,27].”
BackgroundThe Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent
Desai, M. P., Labhasetwar, V., Walter, E., Levy, R. J., & Amidon, G. L. (1997) · Pharmaceutical Research · doi:10.1023/a:1012126301290 · Cited by 858 · cited 1×
“A literature search revealed that the in-vivo efficacy of nanoparticles depends on the uptake of nanoparticles by the tumor with the uptake being increased as particle size decreased [26,27].”
BackgroundAlbendazole: a review of anthelmintic efficacy and safety in humans
HORTON, J. (2000) · Parasitology · doi:10.1017/s0031182000007290 · Cited by 386
In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole
Pourgholami, M. H., Woon, L., Almajd, R., Akhter, J., Bowery, P., & Morris, D. L. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00382-2 · Cited by 139
Self-citationHossein Pourgholami, M., Yan Cai, Z., Lu, Y., Wang, L., & Lawson Morris, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1181 · Cited by 100 · cited 2×
“has been explored as a potential inhibitor of VEGF [11], hypoxia inducible factor 1-α [12] and tumor angiogenesis”
BackgroundPourgholami, M. H., Szwajcer, M., Chin, M., Liauw, W., Seef, J., Galettis, P., Morris, D. L., & Links, M. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1157-8 · Cited by 69
Self-citationEhteda, A., Galettis, P., Pillai, K., & Morris, D. L. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-86 · Cited by 44
Self-citation
Cited by
Protein Nanoparticles: Promising Platforms for Drug Delivery Applications
Jain, A., Singh, S. K., Arya, S. K., Kundu, S. C., & Kapoor, S. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01098 · Cited by 308
Nanotechnology for angiogenesis: opportunities and challenges
Kargozar, S., Baino, F., Hamzehlou, S., Hamblin, M. R., & Mozafari, M. (2020) · Chemical Society Reviews · doi:10.1039/c8cs01021h · Cited by 262
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
Son, D.-S., Lee, E.-S., & Adunyah, S. E. (2020) · Immune Network · doi:10.4110/in.2020.20.e29 · Cited by 130
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022) · Cancers · doi:10.3390/cancers14194601 · Cited by 55
Metadata
- Authors
- Noorani, L., Stenzel, M., Liang, R., Pourgholami, M. H., & Morris, D. L.
- Venue
- Journal of Nanobiotechnology
- Published
- 2015-03-25
- Volume
- 13
- Issue
- 1
- Pages
- 25-25
- ISSN
- 1477-3155 (ISSN-L)
- OpenAlex
- W2011841487
- Cited by
- 103
- References
- 9
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model. https://app.cochat.ai/papers/10.1186/s12951-015-0082-8
- The paper
- Noorani, L., Stenzel, M., Liang, R., Pourgholami, M. H., & Morris, D. L. (2015). Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-015-0082-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.